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Cholangiocarcinoma constitutes a heterogeneous group of malignancies that can emerge 
at any point of the biliary tree. Cholangiocarcinoma is classified into intrahepatic, perihilar 
and distal based on its anatomical location. Histologically, conventional perihilar/distal 
cholangiocarcinomas are mucin-producing adenocarcinomas or papillary tumors; 
intrahepatic cholangiocarcinomas are more heterogeneous and can be sub-classified 
according to the level or size of the displayed bile duct. Cholangiocarcinoma develops 
through multistep carcinogenesis and is preceded by dysplastic and in situ lesions. Definition 
and clinical significance of precursor lesions, including biliary intraepithelial neoplasia, 
intraductal papillary neoplasms of the bile duct, intraductal tubulopapillary neoplasms and 
mucinous cystic neoplasm, are discussed in this review. 
A main challenge in diagnosing cholangiocarcinoma is the fact that tumor tissue for 
histological examination is difficult to obtain. Thus, a major clinical obstacle is the 
establishment of the correct diagnosis at a tumor stage that is amenable to surgery which 
still represents the only curable therapeutic option. Current standards, methodology, and 
criteria for diagnosis are discussed. Cholangiocarcinoma represents a heterogeneous tumor 
with regard to molecular alterations. In intrahepatic subtype, mainly two distinctive morpho-
molecular groups can currently be discriminated. Large-duct type intrahepatic 
cholangiocarcinoma shows a high mutation frequency of oncogenes and tumor suppressor 
genes, such as KRAS and TP53 while Isocitrate Dehydrogenase 1/2 mutations and 
Fibroblast Growth Factor Receptor 2-fusions are typically seen in small-duct type tumors. It 
is most important to ensure the separation of the given anatomical subtypes and to search 
for distinct subgroups within the subtypes on a molecular and morphological basis. 
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Key points  
- Gross and histological classification of cholangiocarcinoma is based on the anatomy and 
histology of the biliary tree.  
- Specific precursor lesions with variable rates of malignant progression are recognised.  
- Adequate diagnosis of CCA may be challenging in daily practice and relevant issues for 
diagnosis are discussed 
- Molecular alterations in cholangiocarcinoma are heterogeneous and correspond to 
morphological subtypes 



















Anatomical and histological appearance of cholangiocarcinoma 
Cholangiocarcinoma (CCA) constitutes a heterogeneous group of malignancies that can 
emerge at any point of the biliary tree.1 It can arise from epithelial cells in the biliary surface 
epithelium (i.e. cholangiocytes) and in peribiliary glands,2and possibly also from progenitor 
cells or even mature hepatocytes.3 
 
Anatomy of the biliary tree 
The biliary tree system is highly heterogeneous and varies in size and morphology, ranging 
from the canals of Hering to the choledochus.4,5 The biliary tree can be subdivided into 
intrahepatic and extrahepatic parts (Figure 1A).4,6 The intrahepatic biliary tree starts at the 
level of canals of Hering, which connect bile canaliculi between adjacent hepatocytes to bile 
ductules and interlobular bile ducts.7 Interlobular bile ducts continue into septal, area, and 
segmental bile ducts. Based on their size, interlobular  and septal bile ducts are considered 
as small intrahepatic bile ducts (< 300 μm in diameter); whereas area and segmental are 
considered as large intrahepatic bile ducts (> 300 μm in diameter).6,8 Small and large 
intrahepatic ducts further differ in terms of histological and embryological features.6,8 Small 
intrahepatic ducts are lined with small and cuboidal-shaped cholangiocytes while the surface 
epithelium of large ducts is composed of tall and cylindric cholangiocytes and variably 
contains mucin-producing cells.6,8 A unique feature of large intrahepatic bile ducts is the 
presence of glands within the duct wall, known as glands of the biliary tree or peribiliary 
glands (PBGs).9,10 Embryologically, small intrahepatic bile ducts originate from the 
remodelling of the ductal plate, while large ducts derive from the elongation of hepatic ducts 
at liver hilum.5 The extrahepatic biliary tree comprises the right and left hepatic ducts, the 
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common hepatic duct, the bile duct (i.e. choledochus), the cystic duct, and the gallbladder.6 
The proximal portion of the extrahepatic bile duct is collectively called the “perihilar bile 
ducts”.4,6,11,12 Peribiliary glands are physiologically distributed along extrahepatic bile ducts 
and are more numerous in perihilar ducts compared to the choledochus.13 
 
Anatomical classification of cholangiocarcinoma, gross morphology and growth patterns  
The classification of CCAs is based on the gross anatomy and histology of the biliary tree.1 
On the basis of anatomical location (Figure 1B), CCA is classified into intrahepatic CCA 
(iCCA), perihilar CCA (pCCA), and distal CCA (dCCA).11,14 Anatomically, iCCA is defined as 
a malignancy located in the periphery of the second-order bile ducts; thus it can arise from 
segmental bile ducts to smaller branches of the intrahepatic biliary tree.11 pCCA arises in 
the right and/or left hepatic duct and/or at their junction;15 it is clinically also known as 
Klatskin tumor,16 although this term should be discouraged. dCCA involves the common bile 
duct.1,17 
Intrahepatic CCA can present three main patterns of growth based on its gross 
appearance (Figure 1C): mass-forming (MF), periductal infiltrating (PI), and intraductal 
growing (IG).1,15 MF-type is the most common growth pattern, accounting for about 65% of 
all iCCA18; it presents as a mass lesion in the hepatic parenchyma; MF-type iCCA is 
generally thought to arise in small intrahepatic bile ducts, and is commonly characterized by 
central necrosis or scarring.1,2,15 PI-type iCCA (6% of iCCA) grows longitudinally along the 
wall of large bile ducts (i.e. segmental and area) and spreads along the portal tracts;1,2,15 
this growth pattern is associated with progressive wall thickening and development of 
strictures in affected ducts.1,2,15 The IG-type (4% of iCCA) presents as a polypoid or papillary 
tumor growing towards duct lumina. Variable infiltration of liver parenchyma could be 
present, thus adopting combined features of periductal infiltrating and mass-forming types 
(PI+MF), representing around 25% of iCCA.1,2,15  
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Macroscopically, pCCA and dCCA have similar aspects; they present as flat or poorly 
defined nodular sclerosing tumors often with diffuse infiltration into adjacent structures ( 
80%) and, less frequently, as intraductal papillary tumors.2 The latter corresponds to the IG-
type and the former to the PI-type of iCCA.2 PI-type of iCCA and flat/nodular sclerosing type 
of p/dCCA are often preceded by preinvasive lesions classified as biliary intraepithelial 
neoplasm (BilIN);1,2 similarly, papillary p/dCCA and IG-type iCCA represent the malignant 
progression of intraductal papillary neoplasm of the bile duct (IPNB).1,2 No preinvasive 
lesions of the MF-type iCCA are known.1,2 Precursor lesions of CCA are detailed in a 
separate section of this review. 
 
Histological aspect and classification of cholangiocarcinoma 
Histologically, the vast majority of pCCA and dCCA are mucin-producing adenocarcinomas 
(conventional type) or papillary tumors;2,11 in contrast, iCCAs are more heterogeneous. 
Conventional iCCA is an adenocarcinoma with variable morphological aspects of tubular 
structures, acini formation, and micropapillary architecture.2,11 In general, these tumors are 
well to moderately differentiated adenocarcinomas formed by columnar to cuboidal epithelial 
cells, which resemble biliary epithelial cells.2,11 Desmoplastic stroma and inflammatory 
reactions frequently occur.2,11. Mucin production is variably present in the lumen of tubular 
structures, in the apical side of tumor cells, and in the cell cytoplasm.2,11 Tumors may show 
a compressive growth against liver parenchyma or display invasion of hepatocyte plate and 
sinusoids.2,11 
As proposed by Nakanuma et al., conventional iCCA can be classified into two main 
histological subtypes according to the level or size of the displayed bile duct (Figure 2A).19–
23 Small bile duct type iCCA may derive from small intrahepatic bile ducts, progenitor cells 
and mature hepatocytes and presents as small-sized tubular or acinar adenocarcinoma with 
nodular growth and invading liver parenchyma; these tumors show no or minimal mucin 
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production.3,19–23 In general, small bile duct type iCCA has a MF growth pattern and is 
peripherally located.2 Large bile duct type iCCA arises from large intrahepatic (i.e. segmental 
and area) bile ducts20 or from associated peribiliary glands;24–26 it is constituted by mucin-
producing columnar tumor cells arranged in a large-duct or papillary architecture.19–23 Tumor 
elements spread along the affected duct with aspects of duct wall and liver parenchyma 
invasion.19–23 Large bile duct type iCCA has usually a PI or, less frequently, IG growth 
patterns and shows a more central location.19–23 Several investigators introduced different 
nomenclatures and proposed distinct criteria for distinguishing the two above-mentioned 
histological subtypes.19–23 Remarkably, the distinction between small and large bile duct 
types does not only have histopathological implications but individuates iCCA subtypes with 
different clinico-pathological and molecular features;19–23 these aspects are discussed later 
in this review. 
The gross and histological features of large bile duct type iCCA are similar to those 
of p/dCCA.2,15,27 Actually, the distinction between iCCA and pCCA at the second-order biliary 
branches is somehow artificial and seems to take into account surgical implications more 
than anatomical, embryological, and molecular aspects.14,23 Moreover, the precise 
anatomical origin of some large tumors can be challenging, as there is no clear evidence 
whether they are by definition intrahepatic or perihilar on gross examination.2,23 These 
aspects corroborate the necessity to develop a combined histomorphological or morpho-
molecular classification of CCA.3 Undoubtedly, the standardization of nomenclature and 
diagnostic criteria is strongly encouraged and will require international consensus among 
pathologists, surgeons, and clinicians. 
Beside conventional and rare variants, cholangiolocarcinoma (CLC) is a further 
histological variant of iCCA and consists of malignant ductular-like structures in an 
anastomosing (“antler-like”) pattern, embedded in a dense, hyalinized stroma (Figure 
2B).14,20,28 Actually, areas of CLC could be found in both large bile duct type and small bile 
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duct type conventional iCCA;19,20 in the former case, tubular adenocarcinoma resembling 
reactive ductules are focally present at the tumor-liver interface.19,20 Remarkably, the World 
Health Organization’s (WHO) Classification included CLC in the group of so-called mixed 
tumors, liver cancers showing a mixed phenotype with varying degrees of both CCA and 
hepatocarcinoma (HCC) features.29 Mixed tumors, representing about 2% of all primary liver 
cancers, are termed combined HCC-CCA (cHCC-CCA) and, by definition, are composed of 
typical HCC and typical iCCA, which may be separate or intermixed (Figure 2C).30 A recent 
international consensus recommended that the diagnosis of cHCC-CCA be based on routine 
histopathology; immunostains may support the diagnosis, but are not essential.30 Molecular 
characterization of cHCC-CCA is still premature. A subgroup of cHCC-CCA has been 
demonstrated to show stem/progenitor features, down-regulation of the hepatocyte 
differentiation program and a commitment to the biliary lineage.31 CLC may be a component 
of cHCC-CCA or a “pure” tumor when more than 80% of the neoplasm shows the CLC 
features. CLC is still a poorly understood type of liver cancer, showing clinico-pathological, 
radiological, and molecular differences from both CCA and HCC.30 Recent molecular data 
support defining CLC as a distinct biliary-derived molecular entity with no HCC traits.32 A 
further subtype of liver cancer with features intermediate between hepatocytes and 
cholangiocytes has been described; the suggested terminology for this tumor is intermediate 
cell carcinoma. Immunostains support features of both hepatocytic and cholangiocytic 
lineage within individual cells.33 
Among rare variants, lymphoepithelioma-like cholangiocarcinoma is worthy to be 
mentioned because it could represent a distinct model of interaction between the immune 
system and neoplastic cells.34 This subtype is defined as a tumor composed of 
undifferentiated epithelial cells with a prominent lymphoid infiltrate and is characterized by 
lower rates of recurrence after surgery and better overall survival. Data on this tumor subtype 
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remain limited;35 however, comprehensive studies could offer precious insights for 
immunotherapeutic strategies. 
 
Precursor lesions of cholangiocarcinoma 
With the exception of MF-iCCA, where the existence of precursor lesions is unknown,1,2 
cholangiocarcinoma develops through multistep carcinogenesis and is preceded by 
dysplastic and in situ lesions. Although precursor lesions specific to the site can be identified 
alongside invasive malignancy in many cases, in situ dysplastic lesions cannot always be 
found. Biliary epithelial neoplasia (BilIN) and intraductal papillary neoplasms of the bile duct 
(IPNB) are well-defined precursor lesions, and intraductal tubulopapillary neoplasms (ITPN) 
and mucinous cystic neoplasm (MCN) have been more recently accepted as premalignant. 
Rare cases of von Meyenburg complexes associated with CCA are reported in the 
literature. 36,37 However, given the prevalence of von Meyenburg complexes in adults is 
5.6%38 and the number of reported cases is so low, their occasional co-existence with CCA 
is likely a reflection of their prevalence rather than representing evidence for a premalignant 
role. 
 
Biliary epithelial neoplasia (BilIN) 
Biliary epithelial neoplasia (BilIN) is flat or micropapillary dysplasia within the biliary tree, 
whose nomenclature is analogous to that described at other sites.39 In common with flat 
intraepithelial neoplasia at other sites, BilIN can be classified based on the degree and intra-
epithelial extent of cellular and nuclear atypia into three grades,  BilIN-1 – 3.40,41 BilIN-3 is 
considered to be carcinoma-in-situ. 
In brief, BilIN-1 shows mild cellular and nuclear atypia or enlargement, and little loss 
of cellular polarity. BilIN-2 shows more obvious changes in addition to the loss of polarity, 
but not amounting to carcinoma-in-situ. BilIN-3 shows widespread loss of polarity, often with 
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cellular and nuclear atypia. Inter-observer agreement using this system of classification is 
moderate.40 This classification has been validated as independent of underlying chronic 
biliary injury. 
The diagnostic challenges posed by flat dysplasia in the biliary tree are common to 
those faced at other sites. Distinguishing BilIN-1 from reactive atypia can occasionally be 
difficult, and the presence of intraepithelial neutrophils may favour a reactive diagnosis. The 
use of ‘indefinite for dysplasia’ has been proposed in cases where sufficient doubt precludes 
definitive classification.  
Although classification of BilIN is based upon cellular and architectural morphology, 
immunohistochemical features, reflecting underlying mutational status, have also been 
suggested as an adjunct to aid diagnosis. For example, expression of mucins MUC1, MUC2 
and MUC5AC, and expression of cell cycle-related proteins such as cyclin D1, p21 and p53 
increases with progression towards invasive malignany.42,43 CD15 expression has recently 
been described as a potential aid to distinguish dysplastic from non-dysplastic biliary 
lesions.44 
Intra- and extra-hepatic cholangiocarcinomas arise more frequently in patients with a 
chronic biliary injury. This may be secondary to liver fluke infection (Clonorchis sinensis and 
Opisthorchis viverrini), in patients with Primary Sclerosing Cholangitis (PSC), or a 
consequence of chronic biliary stone disease or cysts. The development of dysplasia also 
shows similar relationships with the underlying cause. 
Dysplasia was identified in 37% of explants from patients with PSC who received liver 
transplantation for medical reasons. This was typically manifest as flat dysplasia although 
additional micropapillary or papillary dysplasia was frequently found, and a variety of 
metaplastic changes were also present. Dysplasia in these cases was usually limited to 1-3 
ducts but was more widespread in some cases.45  
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In patients with PSC-associated cholangiocarcinoma, BilIN was more frequently 
identified than in PSC explants without cholangiocarcinoma; 83% of explants contained 
BilIN-2 or -3, and greater numbers of ducts with dysplasia were also identified in the setting 
of co-existent cholangiocarcinoma.45 
BilIN has been documented in patients with non-biliary chronic liver disease, 
particularly those with alcohol or chronic HCV infection.46,47 Although less formally 
described, the development of cholangiocarcinoma in patients with liver fluke infection is 
also likely to develop through a sequence of biliary epithelial hyperplasia and dysplasia.48 
Biliary dysplasia has also been documented in association with sporadic cases of 
cholangiocarcinoma.49 
 
Intraductal papillary neoplasms of the bile duct (IPNB) 
IPNBs can be considered the biliary manifestation of the classical adenoma-carcinoma 
sequence of the intestine. This category comprises a range of previous terminologies and 
entities. They may arise within intra- or extra-hepatic ducts and may be multiple. They can 
present clinically as a consequence of large duct obstruction, with cholestatic derangement 
of liver function tests and jaundice.  
IPNBs are yellow, friable papillary lesions found within the duct system. They can be 
single or multiple, and they typically have fine fibrovascular stalks. The cytological features 
of the neoplastic epithelium allow classification of IPNBs into pancreaticobiliary, intestinal, 
gastric, and oncocytic types in the manner used for the equivalent pancreatic lesions, 
intraductal papillary mucinous neoplasms (IPMN).  
Pancreaticobiliary and intestinal subtypes are most common, although their 
frequency varies with geography.50,51 The intestinal subtype resembles a classical colonic 
neoplasm. Dysplasia is most often high-grade, however it can be of any grade in the 
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neoplastic papillary epithelium, and epithelium of the duct in which the IPNB arises often 
shows flat dysplasia.52–54 
An associated invasive cholangiocarcinoma can be identified in approximately half of 
the cases of IPNB.50 Invasive cholangiocarcinoma can be found in association with any 
subtype although is more often associated with the pancreaticobiliary subtype. The 
morphology of the associated malignancy varies depending on the subtype of IPNB with 
which it is associated. Invasive carcinomas associated with the pancreaticobiliary, gastric 
and oncocytic subtype are typically tubular adenocarcinoma, and intestinal subtype 
associated invasive carcinomas are often mucinous adenocarcinomas. The pattern of 
mucins and immunohistochemical phenotype also differ between IPNB subtypes.52 
IPNBs are reportedly more frequent in the Far East, without a significant inheritable 
risk or gender predilection.55 Their geographic distribution reflects their frequent 
development in patients with hepatolithiasis and liver fluke infection, both much more 
common in those areas.51,56 In the West, they are usually sporadic. The most common 
clinical presentations are right upper quadrant abdominal pain, acute cholangitis, and 
obstructive jaundice. Acute cholangitis is observed in 5-59% of patients with IPNB, in 
contrast to cholangiocarcinoma. 
Where IPNBs exhibit dysplasia of any grade but without structural atypia or areas 
suspicious for stromal invasion into papillary cores, the prognosis after resection is excellent. 
Lesions with structural atypia or those suspicious for papillary stromal invasion have a better 
outcome than those with concurrent invasive carcinoma.54 
 
Mucinous cystic neoplasm (MCN) 
Mucinous cystic neoplasms of the bile duct (MCN-B) represent <5% of cystic lesions within 
the liver57 and are similar to their pancreatic and ovarian counterparts. They are associated 
with the development of invasive carcinoma, as in the pancreas. 
 14 
MCN-Bs are usually multilocular cysts with septation, or show a cyst-in-cyst 
appearance on pre-operative imaging.57 The epithelium is usually simple biliary type 
epithelium without significant atypia, overlying characteristic ovarian-type stroma. Focal flat 
or micropapillary dysplasia can be observed in a minority of cases, usually incidentally 
identified by microscopic examination.  
The rate of invasive malignancy is low. Where invasion is present it is usually confined 
to the cystic neoplasm rather than extending into the hepatic parenchyma. Cases are 
identified by greater epithelial atypia and stromal invasion. 
MCNs show a strong female predominance and are found in a generally younger age 
range than IPNBs (21-69 years).57 They present with non-specific features associated with 
all liver cysts, for example, right upper quadrant or epigastric pain and abdominal fullness, 
although incidental identification is common. 
Cases of non-invasive MCN have an excellent prognosis when completely resected.  
Where invasion is present, the prognosis remains good if restricted to within the lesion,58 
although good quality follow-up data is lacking.  
Cholangiocarcinoma has been documented in patients with polycystic liver 
disease,59–61 and it has been suggested that the pathogenesis in these cases may be 
dysplasia within existing benign cysts.62 However, the literature does not indicate an 
increased rate of CCA in these patients, nor that cysts should be should be formally 
considered to be premalignant lesions per se. 
 
Intraductal tubulopapillary neoplasms (ITPN) 
Intraductal tubulopapillary neoplasms have recently been described in the pancreas as a 
distinct intraductal neoplasm. Their bile duct counterparts have subsequently been 
identified.63,64 
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In the pancreas, these are solid and nodular lesions that dilate pancreatic ducts. They 
demonstrate necrosis and high-grade dysplasia, and little mucin production.65 Invasion was 
identified in 3 of the 10 cases originally described. MUC5AC expression is absent in these 
neoplasms. 
Fewer biliary ITPNs have been described. They occur in a population with a mean 
age of 60, without gender differences. Biliary ITPNs show the same intraductal growth, 
tubular pattern and focal necrosis as in the pancreas, and have been documented to grow 
up to 15 cm. 
One of the biliary cases first described was associated with lung metastases, 
indicating the malignant potential of these lesions,66 and subsequent case series have 
confirmed a high risk of malignancy, demonstrating invasive carcinoma, typically tubular 
carcinoma, in 70-80% of cases.53,67 Despite this high rate of associated malignancy, overall 
ITPNs have a prognosis that is favourable when compared with IPNBs. This may reflect 
earlier diagnosis effected by the large in situ intraductal component, or inherent differences 
in the molecular background.53 
 
Current problems in diagnostic pathology of cholangiocarcinoma  
It is challenging for clinicians, radiologists and pathologists to establish the diagnosis of 
CCA. The difficult diagnosis potentially results in delayed surgery, which has a negative 
impact on the chance of curative treatment. Moreover, a pathologically confirmed diagnosis 
is often required before starting chemotherapy in patients for whom surgery is not an option.  
One of the main issues in the diagnosis of CCA is the fact that tumor tissue for 
histological examination is difficult to obtain, particularly in pCCA and dCCA.68 Bile duct 
brush cytology during endoscopic retrograde cholangiopancreatography (ERCP) is the 
reference standard used in daily practice, but yields a low sensitivity (range of 20-55%).68–
71 This is due to the fact that the bile duct may be difficult to access. Moreover, a periductal 
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growth pattern of CCA and pronounced stromal reaction may compromise the technical 
procedure and harvesting of lesional cells and/or tissue. A particular challenging issue is 
distinguishing malignant strictures from benign strictures in patients with PSC, which is one 
of the most important risk factors for cholangiocarcinoma. In PSC, strictures develop in the 
context of inflammation and fibrosis. In benign strictures, inflammation causes reactive 
cytological changes that may mimic neoplasia. Specificity for cytology in patients without 
PSC varies between 82 to 100%.69,70 Additional molecular techniques, including 
fluorescence in situ hybridization (FISH) for detection of polysomy with fluorescently labeled 
DNA probes to the pericentromeric regions of chromosomes 3, 7, and 17, and/or to 
chromosomal band 9p21 deletion may be helpful in increasing sensitivity (up to 50-70%) 
while maintaining specificity, particularly  in non PSC-patients and if combined with 
conventional brush cytology.69,70  
Cell blocks may be helpful to improve cytological evaluation. Additional molecular 
techniques, such as FISH or DNA flow cytometry data, may indicate dysplasia rather than 
invasive cancer in PSC patients.69,72 Results should always be interpreted in the clinical 
context and the presence of additional risk factors, such as a dominant stricture on imaging 
and/or elevation of CA19.9 in serum, increases the probability of CCA in PSC patients.71 
Other inflammatory diseases, such as IgG4 associated cholangitis, are also mimickers of 
CCA, resulting in a substantial number of unnecessary liver resections. IgG4 cholangitis is 
treated with steroids and typically shows a striking/prompt response. Treatment response 
helps in establishing the diagnosis.73 A recent study showed that inflammation alone was 
found in 15% of resections for presumed pCCA, of which 42% could be diagnosed as IgG4-
related cholangitis.74 However, numbers of IgG4 positive plasma cells may be increased in 
the presence of pancreatobiliary malignancies.75 Additional histological criteria, described in 
the context of IgG4-related disease, such as storiform fibrosis, obliterative phlebitis and 
dense lymphoplasmacytic infiltrates may improve correct interpretation of an increase in 
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numbers of IgG4 positive plasma cells.76 Again, histological findings must be interpreted in 
the clinical setting. Composite scores, such as HISORt criteria (histology, imaging, serology, 
other organ involvement, response to treatment) are used for diagnosis.77 Blood-based 
diagnostics may provide a window of opportunity in differentiating between malignant and 
benign strictures. New diagnostic tests, such as IgG/IgG4 RNA ratio, may improve pre-
operative diagnosis and avoid unnecessary surgery. IgG/IgG4 RNA ratio was shown to have 
a sensitivity of 94% and specificity of 99% for the diagnosis of IgG4-related disease, when 
compared to ratios in patients with PSC or pancreaticobiliary malignancies.78 
Only a minority of CCAs occur in the liver (<10%, iCCA). Histological mimickers of 
iCCA include intrahepatic metastases from other primary tumors, such as gastric or 
pancreatic carcinomas. Immunohistochemical staining for markers such as CRP, possibly 
in combination with N-cadherin, may be of help in correctly identifying the tumor of origin if 
the clinical work-up is unclear. CRP was shown to be more frequently positive in iCCA than 
in liver metastasis of other primary tumors.79 Furthermore, the CLC subtype of iCCA, which 
morphologically resembles reactive ductular proliferation, frequently expresses NCAM 
(CD56) and vimentin with increased expression of p53 and ki-67. However, the distinction 
between CLC and reactive ductular reaction may remain challenging, since NCAM 
expression is seen in ductular reaction as well.28,80 
Finally, the distinction between a solid iCCA and hepatocellular carcinoma (HCC) 
may be difficult solely on the basis of morphology. Immunohistochemical markers that are 
indicative of hepatocellular differentiation include HepPar-1 (hepatocyte in paraffin 1), 
Arginase-1, Alpha-fetoprotein (AFP), pCEA (canalicular) and CD10 (canalicular). Markers 
indicative of biliary differentiation include CK7, CK19 and epithelial membrane antigen 
(EMA).29,30 Serum biomarkers, including CA 19-9, alpha-fetoprotein and glypican-3 are of 
limited value in distinguishing both tumors.81 HCC and iCCA have, at least partially, common 
risk factors and overlapping oncogenic pathways. Correct diagnosis is important because of 
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different treatment strategies. In 2-5% of primary liver tumors, mixed features of both CCA 
and HCC are seen (cHCC-CCA). Thus, extensive sampling is necessary to decrease the 
potential contribution of tumor heterogeneity, the latter being a particular issue in pre-
operative biopsies. Agreement on diagnosis, including morphological characteristics in 
relation to the use of additional immunohistochemical stains for the identification of 
hepatocellular and/or biliary differentiation, and agreement on nomenclature and reporting 
is very important for a deeper understanding of cHCC-CCA, for future research strategies 
and multicenter collaboration.3,29,30,82 
After surgical excision, correct pathology reporting of CCA-specimens is of utmost 
importance. For CCA in general, there is room for improvement in terms of prognostic value 
of clinicopathological features.83,84 The definition used for R-status (0 or < 1 mm) and the 
different margins evaluated are not always clearly described in studies. In resection 
specimens of pCCA, it has been shown that important prognostic histological features are 
missing in a substantial number of pathology reports, confirming the complexity of adequate 
reporting. Chatelain et al. reviewed 263 reports from 22 hepatopancreaticobilairy centers. 
Tumor differentiation was missing in 27% of cases, vascular invasion in 45% and infiltration 
of the bile duct surgical margins in 4% of the reports. Moreover, distances between the tumor 
and the vessel margin, liver margin and the periductal soft tissue circumferential margin 
were not specified in 87%, 79%, and 89% of cases, respectively.85 The inadequacy of 
reporting may be key to explaining the finding that even after R0 resection, (local) recurrence 
rates have been reported to be more than 50%.86 The prognostic value of the new, 8th 
edition of the American Joint Committee on Cancer staging system also deserves further 
study, since a recent study showed that overall prognostic performance of the 8th edition 
was not markedly improved over the 7th edition.87  
The inclusion of all potentially relevant parameters, such as resection and dissection 
planes in the pathology report is essential for adequate staging, for the correct interpretation 
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of residual disease status, and last but not least for scientific research. In this modern area 
of molecular research and novel (molecular) treatments, it is of great importance that the 
basis pathology data are translated and reported in an accurate way. Consensus among all 
clinicians involved in diagnosis and treatment of CCA, and a coordinated approach both in 
the clinical and research setting, is warranted to improve diagnosis, prognosis and treatment 
options in CCA. 
 
4. Molecular pathology of CCA 
After a long period of standstill, numerous new molecular alterations in CCA have been 
discovered within the last few years. Recent advances are largely due to the employment of 
technical innovations in high-throughput molecular analyses and the more or less strict 
separation of CCA subtypes. Evolving molecular data and the understanding of underlying 
mechanisms are not only helpful for improving the characterization of CCA and its subtypes 
but might also pave the way for personalized medicine for these rare cancer types in most 
countries. For future studies it is most important to ensure the separation of the given 
anatomical subtypes and to search for distinct subgroups within the subtypes on a molecular 
and morphological basis. This goal of a new morpho-molecular classification of CCA can 
only be reached if clinicopathologically well-characterized cohorts are used. 
Current knowledge of genomic and epigenomic alterations characterizes CCA as a highly 
heterogeneous tumor; however, available molecular data are partly conflicting. Several 
reasons might account for this: geographic, ethnic, and etiological differences of study 
populations, usage of different detection methods, and misclassifications (e.g. pCCA and 
iCCA or dCCA and pancreatic adenocarcinoma). Therefore, the status quo of molecular 
alterations in CCA is imprecise, and further work is required to accomplish more accurate 
data by employing better clinicopathologically characterized and more homogenous (e.g. 
monoetiological) study populations. 
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Molecular alterations of intrahepatic cholangiocarcinoma 
Partly due to the reasons mentioned, there is a high variation of mutation frequencies in 
iCCA. Nonetheless, the anatomical differences described above (large vs small-duct type 
iCCA) are reflected in the molecular picture we have seen so far, i.e. mainly two distinctive 
morpho-molecular groups of iCCA can currently be discriminated. Large-duct type iCCAs 
show a high mutation frequency of oncogenes and tumor suppressor genes, such as KRAS 
(15-30%) and TP53 (10-40%).22,88–91 Large-duct type iCCAs typically lack IDH1/2 mutations 
and FGFR2-fusions, features typically seen in small-duct iCCA. Apart from these high-
frequency mutations, other genes, such as BRAF, BAP1, PIK3CA, GNAS, ARID1A, SMAD4, 
PTEN, MDM2, EGFR, ERBB2/HER2 and many more, are mutated; however usually in a 
much lower frequency in most cohorts. Some of them, although usually low in frequency, 
are easy to test and might serve as a putative therapeutical target with available drugs that 
have proven efficacy in other tumor types (e.g. for ERBB2 and BRAF mutations).92–94 
Microsatellite instability (MSI) is another putative predictive and therapeutically relevant 
marker, since it has been shown that DNA-mismatch repair-deficient tumors are significantly 
more responsive to immune checkpoint blockade. MSI was detected in up to 30% of CCA, 
particularly in liver-fluke associated tumors,95 whereas, in non-liver-fluke associated CCA 
MSI seems to be a rare event.96  
In contrast, small-duct type iCCAs are typically of mass-forming type and show 
IDH1/2 mutations (10-30%) and FGFR2-fusions (10-25%).88–91,97–99 From a diagnostic point 
of view, these molecular alterations fairly restricted to iCCA can be used to improve the 
classification of anatomical “borderline cases”, e.g. to discriminate perihilar from intrahepatic 
CCA. Additionally, BAP1 mutations were found to be restricted to iCCA in some studies and 
BAP1 and IDH mutations were also found in HCC, suggesting an overlap of iCCA, cHCC-
CCAs and HCC, respectively a common cell-of-origin for at least some of these mass-
 21 
forming, small-duct type iCCAs.97,100–103 As cHCC-CCAs represent a separated tumor type, 
according to the current WHO classification, and mostly vary in their molecular profile 
significantly to iCCA, this will not be further discussed in this review.30 Furthermore, TP53 
mutations may be used as a surrogate marker for malignancy (e.g. by 
immunohistochemistry to discriminate untypical bile duct adenomas (BDA) from iCCA). It is 
noteworthy that BDA often (~50%) exhibit BRAF mutations, and this feature should not be 
misinterpreted as a surrogate marker for malignancy. 
Recent studies have tried to address the etiological distinctiveness of CCA and have found 
significant genomic and epigenomic landscape changes between liver fluke and non-liver 
fluke associated CCA.104,105 Further studies focusing on molecular cholangiocarcinogenesis 
of well-characterized CCA cohorts with distinct etiology (e.g. PSC-associated CCA) are 
needed, and are likely to highlight differences between monoetiological and 
conventional/idiopathic CCA cohorts.  
 
Molecular alterations of extrahepatic cholangiocarcinoma 
Extrahepatic cholangiocarcinoma largely shares the heterogenic molecular pattern with 
large-duct type iCCA, though frequencies of some gene mutations vary significantly (e. g. 
KRAS mutation frequency seems to be higher in pCCA and dCCA compared to iCCA.22,89–
91,106 In particular, IDH1/2 and BAP1 mutations and FGFR2-fusions are typically absent in 
extrahepatic CCA.88–91,98–100 
 
Molecular alterations of precursor lesions 
Little is known on molecular alterations of precursor lesions. Clearly-defined biliary precursor 
lesions, such as intraductal papillary neoplasias of the bile duct (IPNB, intraductal 
tubulopapillary neoplasias of the bile duct (ITPN), and biliary intraepithelial neoplasias 
(BilIN), have been the focus of studies searching for early molecular alterations in 
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cholangiocarcinogenesis. However, most studies were conducted as a single gene 
approach, and systematic genome-wide screening approaches are lacking, to date. For 
IPNB, involvement of common molecular pathways have been described, for instance, 
KRAS mutations were described in up to 46%.50,107 Another study found recurrent mutations 
in the Wnt/β-catenin signaling pathway in IPNB.108 However, the few studies available are 
already conflicting, as GNAS mutations were found in 50% of IPNB in one study, whereas 
another study showed a low GNAS mutation level of <5%.107,109 Due to difficulties in 
microdissecting BilIN lesions, there is no meaningful study on molecular alterations in BilIN 
available to date. For ITPN, similar alterations could be detected in a study of 20 cases; 
however CDKN2A/p16 mutations were found in a high proportion (44%) in this cohort.53 
 
Epigenetic alterations in cholangiocarcinogenesis 
CCA is a highly epigenetic regulated tumor type. Epigenetic mechanisms involved in gene 
regulation typically include histone modification, DNA methylation, and noncoding RNAs. 
However, not all of these mechanisms have been studied sufficiently in human CCA cohorts. 
Systematic studies focusing on DNA methylation changes are available and genome-wide 
methylation patterns in CCA were first described in 2014.104,110,111 
For a more detailed description of epigenetic and genetic alterations in 
cholangiocarcinogenesis, see the other reviews in this issue. 
 
Concluding Remarks 
Morphologically, cholangiocarcinoma is a heterogeneous group of malignancies; this histo-
morphological heterogeneity is strictly associated with cell of origin, pathogenesis, 
underlying liver disease, and molecular alterations. These aspects corroborate the necessity 
to develop a combined morpho-molecular classification of CCA. Up to date, no international 
consensus on histological classification is present and the standardization of nomenclature 
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and diagnostic criteria is strongly required. Furthermore, experimental models and clinical 
studies do not take in full consideration differences in CCA with distinct morphological 
features. The application of novel tools on histological images (e.g. deep convolutional 
neural network112) could help in tumour classification and be relevant in stratify patients’ 
prognosis and predict mutation status. 
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Figure 1. A) The biliary tree is subdivided into the intrahepatic (light green) and extrahepatic 
parts (dark green). Based on their size, interlobular and septal bile ducts are considered as 
small intrahepatic bile ducts while segmental and area are considered as large intrahepatic 
bile ducts. The extrahepatic biliary tree comprises the right and left hepatic ducts, the 
common hepatic duct, the bile duct (i.e. choledochus), the gallbladder, and the cystic duct. 
B) Based on its location, cholangiocarcinoma (CCA) is classified into intrahepatic CCA, 
perihilar CCA, and distal CCA. Intrahepatic CCA is a malignancy located proximal to the 
second-order bile ducts. Perihilar CCA arises in the right and left hepatic duct or at their 
junction. Distal CCA involves the common bile duct. C) Intrahepatic (i) cholangiocarcinoma 
(CCA) can present three main patterns of growth based on its gross appearance: mass-
forming (MF), periductal infiltrating (PI), and intraductal growing (IG). MF-type presents as 
a mass lesion in the hepatic parenchyma. PI-type grows longitudinally along the wall of large 
bile ducts. The IG-type presents as a polypoid or papillary tumor growing towards duct 
lumina. Perihilar (p) and distal (d) can present only PI- and IG-growth patterns. 
 
Figure 2. A) Conventional intrahepatic (i) CCA is an adenocarcinoma with variable 
morphological aspects of tubular structures, acini formation, and micropapillary architecture. 
Conventional iCCA can be classified into two main histological subtypes: small bile duct type 
iCCA presents as small-sized tubular or acinar adenocarcinoma with no or minimal mucin 
production. Large bile duct type iCCA is constituted by mucin-producing columnar tumor 
cells arranged in a large-duct or papillary architecture;large bile duct type iCCA latter 
corresponds histologically to conventional perihilar and distal CCA. B) Beside conventional, 
cholangiolo-carcinoma (CLC) is a further histological variant of iCCA and consists of 
malignant ductular-like structures in an anastomosing pattern embedded in a dense, 
hyalinized stroma. C) Combined (c) HCC-CCA is composed of typical HCC and typical 
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iCCA, which may be intermixed or separated. H&E: Hematoxylin & Eosin; K7: cytokeratin 7; 
PAS: Periodic-Acid od Schiff; BD: bile ducts; PI: periductal infiltrating; IG: intraductal 
growing; MF: mass forming. Scale Bars= 200 µm 
 
Figure 3. Precursor lesions. A) Intraductal papillary neoplasm of the bile duct (IPNB) is an 
intraductal lesion with dysplastic epithelium, analogous to pancreatic intraductal papillary 
mucinous neoplasms (IPMN). Scale Bars= left and centre panel 5 mm, right panel 100 µm. 
B) Biliary epithelial neoplasia (BilIN) is flat or micropapillary dysplasia within the biliary tree, 
whose nomenclature is analogous to that described at other sites. Scale Bar= 100 µm. C) 
Mucinous cystic neoplasms (MCN) of the bile duct are similar to their pancreatic and ovarian 
counterparts, usually simple biliary type epithelium without significant atypia overlying 
characteristic ovarian-type stroma. Scale Bar= 100 µm. D) Intraductal tubulopapillary 
neoplasms (ITPN) show the same solid or nodular intraductal growth, tubular pattern and 
focal necrosis as equivalent pancreatic lesions. Scale Bar= 1 mm. 
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